IRB #

STUDY00016804

Title

A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients
with Advanced Malignancies

Principal Investigator

Matthew Taylor

Study Purpose

This study is being done to test the good and bad effects of DCC-3014-01-001 in patients with breast cancer, prostate cancer, gastric cancer, ovarian cancer or non-small cell lung cancer.

Medical Condition(s)

Breast cancer;
Prostate cancer;
Gastric cancer;
Ovarian cancer;
non-small cell lung cancer (NSCLC)

Eligibility Criteria

1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 90

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. 30 days after last dose of study drug, participants will have a follow-up visit.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Deciphera Pharmaceuticals, LLC

Recruitment End

05/31/2019

Compensation Provided

No


Go Back